RG

REGENXBIO

- NASDAQ:RGNX
Last Updated 2021-09-24

LinkedIn Profile

Access REGENXBIO historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Sector Industry
nasdaq:rgnx 440337 Aug 11th, 2021 12:00AM REGENXBIO Inc. 22K 306.00 Open Biotechnology Aug 10th, 2021 11:17PM Aug 10th, 2021 11:17PM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, Gene Therapy Open 9600 Blackwell Road, Suite 210 Rockville Maryland (MD) US 20850 Health Care Pharmaceuticals & Biotechnology
nasdaq:rgnx 440337 Aug 10th, 2021 12:00AM REGENXBIO Inc. 22K 306.00 Open Biotechnology Aug 10th, 2021 10:47AM Aug 10th, 2021 10:47AM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, Gene Therapy Open 9600 Blackwell Road, Suite 210 Rockville Maryland (MD) US 20850 Health Care Pharmaceuticals & Biotechnology
nasdaq:rgnx 440337 Aug 9th, 2021 12:00AM REGENXBIO Inc. 22K 306.00 Open Biotechnology Aug 9th, 2021 09:37AM Aug 9th, 2021 09:37AM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, Gene Therapy Open 9600 Blackwell Road, Suite 210 Rockville Maryland (MD) US 20850 Health Care Pharmaceuticals & Biotechnology
nasdaq:rgnx 440337 Aug 8th, 2021 12:00AM REGENXBIO Inc. 22K 306.00 Open Biotechnology Aug 8th, 2021 06:37PM Aug 8th, 2021 06:37PM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, Gene Therapy Open 9600 Blackwell Road, Suite 210 Rockville Maryland (MD) US 20850 Health Care Pharmaceuticals & Biotechnology
nasdaq:rgnx 440337 Aug 7th, 2021 12:00AM REGENXBIO Inc. 22K 306.00 Open Biotechnology Aug 6th, 2021 11:34PM Aug 7th, 2021 05:27PM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, Gene Therapy Open 9600 Blackwell Road, Suite 210 Rockville Maryland (MD) US 20850 Health Care Pharmaceuticals & Biotechnology
nasdaq:rgnx 440337 Aug 6th, 2021 12:00AM REGENXBIO Inc. 22K 306.00 Open Biotechnology Aug 6th, 2021 09:47AM Aug 6th, 2021 09:47AM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, Gene Therapy Open 9600 Blackwell Road, Suite 210 Rockville Maryland (MD) US 20850 Health Care Pharmaceuticals & Biotechnology
nasdaq:rgnx 440337 Aug 5th, 2021 12:00AM REGENXBIO Inc. 22K 305.00 Open Biotechnology Aug 5th, 2021 12:50AM Aug 5th, 2021 02:01PM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, Gene Therapy Open 9600 Blackwell Road, Suite 210 Rockville Maryland (MD) US 20850 Health Care Pharmaceuticals & Biotechnology
nasdaq:rgnx 440337 Aug 4th, 2021 12:00AM REGENXBIO Inc. 22K 303.00 Open Biotechnology Aug 4th, 2021 09:38AM Aug 4th, 2021 09:38AM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, Gene Therapy Open 9600 Blackwell Road, Suite 210 Rockville Maryland (MD) US 20850 Health Care Pharmaceuticals & Biotechnology
nasdaq:rgnx 440337 Aug 3rd, 2021 12:00AM REGENXBIO Inc. 22K 303.00 Open Biotechnology Aug 3rd, 2021 09:28AM Aug 3rd, 2021 09:28AM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, Gene Therapy Open 9600 Blackwell Road, Suite 210 Rockville Maryland (MD) US 20850 Health Care Pharmaceuticals & Biotechnology
nasdaq:rgnx 440337 Aug 2nd, 2021 12:00AM REGENXBIO Inc. 22K 304.00 Open Biotechnology Aug 2nd, 2021 01:28PM Aug 2nd, 2021 01:28PM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, Gene Therapy Open 9600 Blackwell Road, Suite 210 Rockville Maryland (MD) US 20850 Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.